Login to Your Account



Clinic Roundup


Friday, August 5, 2011
Prolor Biotech Inc., of Nes-Ziona, Israel, said results from a Phase II trial showed that a single weekly injection of its long-acting CTP-modified version of human growth hormone (hGH-CTP) has the potential to replace seven consecutive daily injections of currently marketed hGH in adults with a growth-hormone deficiency.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription